Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasisulam versus paclitaxel as second-line treatment for metastatic melanoma
NL-OMON34807Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing Tasisulam with Paclitaxel (2 arms). Primary endpoint: Overall survival. Planned start Feb 2010; status: not yet recruiting.
02
Drugs
tasisulampaclitaxel
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON34807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34807.